In LIHC and NSCLC, USP22 acts as a deubiquitinating enzyme for PD-L1, inhibiting the ubiquitin-proteasome degradation pathway of PD-L1 and thus leading to tumor immune escape (Huang et al., 2019; Wang et al., 2020). This evidence concerns the gene USP22 and neoplasm.